Applications of miRNA technology for atherosclerosis - PubMed (original) (raw)

Review

Applications of miRNA technology for atherosclerosis

Hiroe Toba et al. Curr Atheroscler Rep. 2014 Feb.

Abstract

MicroRNAs (miRNAs) are a class of post-transcriptional regulators that provide a mechanism of gene silencing by translational repression or degradation of the targeted gene. Gene expression regulation by miRNAs is involved in most if not all physiological and pathophysiological processes. Atherosclerosis is a major cardiovascular disease pathology regulated by miRNAs. Recent miRNA profiling studies have implicated the potential use of miRNAs as biomarkers in patients with atherosclerosis, as both diagnostic and prognostic indicators. This review will discuss the clinical and basic science research information that has been gleaned regarding miRNA roles in dyslipidemia, diabetes, obesity, and insulin resistance which are the major stimulators for the development of atherosclerosis.

PubMed Disclaimer

Figures

Figure 1

Simplistic overview of miRNA functions in biological processes

Similar articles

• MicroRNAs in atherosclerosis.
  Hosin AA, Prasad A, Viiri LE, Davies AH, Shalhoub J. Hosin AA, et al. J Vasc Res. 2014;51(5):338-49. doi: 10.1159/000368193. Epub 2014 Dec 5. J Vasc Res. 2014. PMID: 25500818 Review.
• MicroRNAs as therapeutic targets in atherosclerosis.
  Loyer X, Mallat Z, Boulanger CM, Tedgui A. Loyer X, et al. Expert Opin Ther Targets. 2015 Apr;19(4):489-96. doi: 10.1517/14728222.2014.989835. Epub 2014 Dec 3. Expert Opin Ther Targets. 2015. PMID: 25464904 Review.
• Diagnostic and theranostic microRNAs in the pathogenesis of atherosclerosis.
  Shoeibi S. Shoeibi S. Acta Physiol (Oxf). 2020 Jan;228(1):e13353. doi: 10.1111/apha.13353. Epub 2019 Aug 10. Acta Physiol (Oxf). 2020. PMID: 31344321 Review.
• Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches.
  Abulsoud AI, Elshaer SS, Rizk NI, Khaled R, Abdelfatah AM, Aboelyazed AM, Waseem AM, Bashier D, Mohammed OA, Elballal MS, Mageed SSA, Elrebehy MA, Zaki MB, Elesawy AE, El-Dakroury WA, Abdel-Reheim MA, Saber S, Doghish AS. Abulsoud AI, et al. Curr Atheroscler Rep. 2024 Aug;26(8):395-410. doi: 10.1007/s11883-024-01216-4. Epub 2024 Jun 13. Curr Atheroscler Rep. 2024. PMID: 38869707 Review.
• MicroRNA Regulation of Atherosclerosis.
  Feinberg MW, Moore KJ. Feinberg MW, et al. Circ Res. 2016 Feb 19;118(4):703-20. doi: 10.1161/CIRCRESAHA.115.306300. Circ Res. 2016. PMID: 26892968 Free PMC article. Review.

Cited by

• MiR-129-5p-mediated Beclin-1 suppression inhibits endothelial cell autophagy in atherosclerosis.
  Geng Z, Xu F, Zhang Y. Geng Z, et al. Am J Transl Res. 2016 Apr 15;8(4):1886-94. eCollection 2016. Am J Transl Res. 2016. PMID: 27186312 Free PMC article.
• BMSCs and miR-124a ameliorated diabetic nephropathy via inhibiting notch signalling pathway.
  Sun J, Zhao F, Zhang W, Lv J, Lv J, Yin A. Sun J, et al. J Cell Mol Med. 2018 Oct;22(10):4840-4855. doi: 10.1111/jcmm.13747. Epub 2018 Jul 19. J Cell Mol Med. 2018. PMID: 30024097 Free PMC article.
• PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications.
  Grbić E, Peterlin A, Kunej T, Petrovič D. Grbić E, et al. Balkan J Med Genet. 2018 Oct 29;21(1):39-46. doi: 10.2478/bjmg-2018-0011. eCollection 2018 Jun. Balkan J Med Genet. 2018. PMID: 30425909 Free PMC article.
• In silico Prediction of miRNA Interactions With Candidate Atherosclerosis Gene mRNAs.
  Mukushkina D, Aisina D, Pyrkova A, Ryskulova A, Labeit S, Ivashchenko A. Mukushkina D, et al. Front Genet. 2020 Nov 4;11:605054. doi: 10.3389/fgene.2020.605054. eCollection 2020. Front Genet. 2020. PMID: 33329752 Free PMC article.
• Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling.
  Chistiakov DA, Sobenin IA, Orekhov AN, Bobryshev YV. Chistiakov DA, et al. Biomed Res Int. 2015;2015:354517. doi: 10.1155/2015/354517. Epub 2015 Jun 29. Biomed Res Int. 2015. PMID: 26221589 Free PMC article. Review.

References

1. 1. Lee RC, Feinbaum RL, Ambros V. The c. Elegans heterochronic gene lin-4 encodes small rnas with antisense complementarity to lin-14. Cell. 1993;75 (5):843–854. - PubMed
2. 1. van Rooij E, Purcell AL, Levin AA. Developing microrna therapeutics. Circ Res. 2012;110(3):496–507. doi:410.1161/CIRCRESAHA.1111.247916. Describes potential for using miRNA for therapeutics. - PubMed
3. 1. Raitoharju E, Lyytikainen LP, Levula M, Oksala N, Mennander A, Tarkka M, Klopp N, Illig T, Kahonen M, Karhunen PJ, Laaksonen R, et al. Mir-21, mir-210, mir-34a, and mir-146a/b are up-regulated in human atherosclerotic plaques in the tampere vascular study. Atherosclerosis. 2011;219(1):211–217. doi:210.1016/j.atherosclerosis.2011.1007.1020. Epub 2011 Jul 1022. Identifies particular miRNAs increased in human atherosclerosis. - PubMed
4. 1. Caolo V, Schulten HM, Zhuang ZW, Murakami M, Wagenaar A, Verbruggen S, Molin DG, Post MJ. Soluble jagged-1 inhibits neointima formation by attenuating notch-herp2 signaling. Arterioscler Thromb Vasc Biol. 2011;31(5):1059–1065. doi:1010.1161/ATVBAHA.1110.217935. Epub 212011 Feb 217917. - PubMed
5. 1. Ma L, Yang J, Runesha HB, Tanaka T, Ferrucci L, Bandinelli S, Da Y. Genome-wide association analysis of total cholesterol and high-density lipoprotein cholesterol levels using the framingham heart study data. BMC Med Genet. 2010;11:55. doi: 10.1186/1471-2350-1111-1155. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

• N01-HV-00244/HV/NHLBI NIH HHS/United States
• P01 HL051971/HL/NHLBI NIH HHS/United States
• HL075360/HL/NHLBI NIH HHS/United States
• P20 GM104357/GM/NIGMS NIH HHS/United States
• R01 HL075360/HL/NHLBI NIH HHS/United States
• HL051971/HL/NHLBI NIH HHS/United States
• HHSN268201000036C/HL/NHLBI NIH HHS/United States
• I01 BX000505/BX/BLRD VA/United States

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Springer

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information